company background image
NEU

Neuren PharmaceuticalsASX:NEU Stock Report

Market Cap

AU$250.7m

7D

-1.0%

1Y

82.6%

Updated

16 Oct, 2021

Data

Company Financials
NEU fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NEU Overview

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders.

Price History & Performance

Summary of all time highs, changes and price drops for Neuren Pharmaceuticals
Historical stock prices
Current Share PriceAU$1.99
52 Week HighAU$0.99
52 Week LowAU$2.53
Beta1.35
1 Month Change-5.24%
3 Month Change22.09%
1 Year Change82.57%
3 Year Change58.57%
5 Year Change111.70%
Change since IPO-73.11%

Recent News & Updates

Aug 06
Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

NEUAU PharmaceuticalsAU Market
7D-1.0%0.04%0.9%
1Y82.6%-2.4%20.2%

Return vs Industry: NEU exceeded the Australian Pharmaceuticals industry which returned -2.4% over the past year.

Return vs Market: NEU exceeded the Australian Market which returned 20.2% over the past year.

Price Volatility

Is NEU's price volatile compared to industry and market?
NEU volatility
NEU Beta1.35
Industry Beta1.3
Market Beta1

Stable Share Price: NEU is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: NEU's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aJon Pilcherhttps://www.neurenpharma.com

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes.

Neuren Pharmaceuticals Fundamentals Summary

How do Neuren Pharmaceuticals's earnings and revenue compare to its market cap?
NEU fundamental statistics
Market CapAU$250.67m
Earnings (TTM)-AU$12.40m
Revenue (TTM)AU$717.00k

349.7x

P/S Ratio

-20.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NEU income statement (TTM)
RevenueAU$717.00k
Cost of RevenueAU$10.11m
Gross Profit-AU$9.39m
ExpensesAU$3.00m
Earnings-AU$12.40m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.098
Gross Margin-1,310.32%
Net Profit Margin-1,728.87%
Debt/Equity Ratio0.0%

How did NEU perform over the long term?

See historical performance and comparison

Valuation

Is Neuren Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

15.06x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NEU's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NEU's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NEU is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: NEU is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NEU's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NEU is overvalued based on its PB Ratio (15.1x) compared to the AU Pharmaceuticals industry average (3.3x).


Future Growth

How is Neuren Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

66.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Neuren Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Neuren Pharmaceuticals performed over the past 5 years?

-2.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NEU is currently unprofitable.

Growing Profit Margin: NEU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NEU is unprofitable, and losses have increased over the past 5 years at a rate of 2.3% per year.

Accelerating Growth: Unable to compare NEU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NEU is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.1%).


Return on Equity

High ROE: NEU has a negative Return on Equity (-74.49%), as it is currently unprofitable.


Financial Health

How is Neuren Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: NEU's short term assets (A$19.0M) exceed its short term liabilities (A$2.4M).

Long Term Liabilities: NEU has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: NEU is debt free.

Reducing Debt: NEU has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NEU has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NEU has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 12.1% each year.


Dividend

What is Neuren Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NEU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NEU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NEU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NEU's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NEU's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Jon Pilcher

1.42yrs

Tenure

Mr. Jonathan Charles Pilcher, also known as Jon, BSc (Hons), ACA serves as Managing Director at Neuren Pharmaceuticals Limited since June 14, 2021. He had been a Company Secretary at Neuren Pharmaceuticals...


Leadership Team

Experienced Management: NEU's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: NEU's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.9%.


Top Shareholders

Company Information

Neuren Pharmaceuticals Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Neuren Pharmaceuticals Limited
  • Ticker: NEU
  • Exchange: ASX
  • Founded: 2001
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$250.672m
  • Shares outstanding: 125.97m
  • Website: https://www.neurenpharma.com

Number of Employees


Location

  • Neuren Pharmaceuticals Limited
  • 697 Burke Road
  • Suite 201
  • Camberwell
  • Victoria
  • 3124
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/16 07:04
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.